HK117395A - (-)-[[4-(1,4,5,6-tetrahydro-4-methyl-6-oxo-3-pyridazinyl)phenyl]hydrazono]propanedinitrile - Google Patents

(-)-[[4-(1,4,5,6-tetrahydro-4-methyl-6-oxo-3-pyridazinyl)phenyl]hydrazono]propanedinitrile

Info

Publication number
HK117395A
HK117395A HK117395A HK117395A HK117395A HK 117395 A HK117395 A HK 117395A HK 117395 A HK117395 A HK 117395A HK 117395 A HK117395 A HK 117395A HK 117395 A HK117395 A HK 117395A
Authority
HK
Hong Kong
Prior art keywords
pct
propanedinitrile
hydrazono
pyridazinyl
tetrahydro
Prior art date
Application number
HK117395A
Other languages
English (en)
Inventor
Pentti Nore
Erkki Honkanen
Reijo Baeckstroem
Tom Wikberg
Heimo Haikala
Jorma Haarala
Original Assignee
Orion Yhtymae Oy
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB919100049A external-priority patent/GB9100049D0/en
Priority claimed from GB919118947A external-priority patent/GB9118947D0/en
Application filed by Orion Yhtymae Oy filed Critical Orion Yhtymae Oy
Publication of HK117395A publication Critical patent/HK117395A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/14—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/04—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having less than three double bonds between ring members or between ring members and non-ring members
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Cardiology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Detergent Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)
  • Cephalosporin Compounds (AREA)
HK117395A 1991-01-03 1995-07-20 (-)-[[4-(1,4,5,6-tetrahydro-4-methyl-6-oxo-3-pyridazinyl)phenyl]hydrazono]propanedinitrile HK117395A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB919100049A GB9100049D0 (en) 1991-01-03 1991-01-03 (-)-6-(4-(dicyanomethylidenehydrazino)phenyl)-4,5-dihydro-5-methylpyridazin-3(2h)one
GB919118947A GB9118947D0 (en) 1991-09-05 1991-09-05 Method for the optical resolution of racemic 6-(4-amino-phenyl)-methyl-pyridazin-3(2h)one and preparation of optically active derivatives thereof
PCT/FI1992/000003 WO1992012135A1 (en) 1991-01-03 1992-01-03 (-)-[[4-(1,4,5,6-tetrahydro-4-methyl-6-oxo-3-pyridazinyl)phenyl]-hydrazono]propanedinitrile

Publications (1)

Publication Number Publication Date
HK117395A true HK117395A (en) 1995-07-28

Family

ID=26298204

Family Applications (1)

Application Number Title Priority Date Filing Date
HK117395A HK117395A (en) 1991-01-03 1995-07-20 (-)-[[4-(1,4,5,6-tetrahydro-4-methyl-6-oxo-3-pyridazinyl)phenyl]hydrazono]propanedinitrile

Country Status (32)

Country Link
US (3) US5424428A (bg)
EP (1) EP0565546B1 (bg)
JP (2) JP2635445B2 (bg)
KR (1) KR100207145B1 (bg)
AT (1) ATE119525T1 (bg)
AU (1) AU645399B2 (bg)
BG (1) BG62002B1 (bg)
BR (1) BR1100737A (bg)
CA (2) CA2099262C (bg)
CY (1) CY1878A (bg)
DE (1) DE69201640T2 (bg)
DK (1) DK0565546T3 (bg)
EE (1) EE02946B1 (bg)
ES (1) ES2070627T3 (bg)
FI (1) FI105183B (bg)
GB (1) GB2251615B (bg)
GE (1) GEP19991868B (bg)
HK (1) HK117395A (bg)
HR (1) HRP921251B1 (bg)
HU (1) HU218659B (bg)
IE (1) IE72101B1 (bg)
IL (2) IL100553A (bg)
LU (1) LU90920I2 (bg)
LV (1) LV11174B (bg)
NO (2) NO300682B1 (bg)
NZ (1) NZ241194A (bg)
PL (2) PL169435B1 (bg)
RO (1) RO111847B1 (bg)
RU (1) RU2118317C1 (bg)
SI (1) SI9112003A (bg)
WO (1) WO1992012135A1 (bg)
YU (1) YU48767B (bg)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2251615B (en) * 1991-01-03 1995-02-08 Orion Yhtymae Oy (-)-[[4-(1,4,5,6-tetrahydro-4-methyl-6-oxo-3-pyridazinyl)phenyl]hydrazono]pro panedinitrile
GB2266841A (en) * 1992-05-06 1993-11-17 Orion Yhtymae Oy Compounds for use as anti-ischemic medicaments
JP2806192B2 (ja) * 1992-11-02 1998-09-30 日本曹達株式会社 血小板凝集抑制剤
AU3855995A (en) * 1994-11-11 1996-06-06 Nippon Soda Co., Ltd. Optically active compound
GB9606474D0 (en) 1996-03-27 1996-06-05 Orion Yhytmo Oy Method for obtaining pure enantiomers of a pyridazinone derivative
GB9614098D0 (en) 1996-07-05 1996-09-04 Orion Yhtymae Oy Transdermal delivery of levosimendan
FI973804A (fi) 1997-09-26 1999-03-27 Orion Yhtymae Oy Levosimendaanin oraalisia koostumuksia
FI974578A (fi) 1997-12-19 1999-06-20 Orion Yhtymae Oyj Menetelmä levosimendaanin antamiseksi
FI980901A (fi) 1998-04-23 1999-10-24 Orion Yhtymae Oyj Levosimendaania säädellysti vapauttavia oraalisia koostumuksia
FI980902A (fi) * 1998-04-23 1999-10-24 Orion Yhtymae Oyj Levosimendaanin stabiileja koostumuksia
FI104718B (fi) * 1998-06-18 2000-03-31 Orion Yhtymae Oyj [[4-(2-atsido-3-metyyli-5-oksotetrahydrofuran-2-yyli)fenyyli]hydratsono]propaanidinitriili käytettäväksi referenssiaineena levosimendaanierien analyysissä
US5905078A (en) * 1998-06-19 1999-05-18 Orion Corporation Use of a pyridazinone derivative
FI981473A (fi) * 1998-06-25 1999-12-26 Orion Yhtymae Oyj Menetelmä pulmonaalihypertension hoitamiseksi
GB9915179D0 (en) * 1999-06-29 1999-09-01 Orion Corp A method for the treatment or prevention of coronary graft vasospasm
FI109659B (fi) 1999-09-10 2002-09-30 Orion Yhtymae Oyj Levosimendaanin farmaseuttisia liuoksia
DE60016038T2 (de) * 1999-10-22 2005-12-22 Orion Corp. Neue verwendung von levosimendan
FI20001542A (fi) 2000-06-29 2001-12-30 Orion Yhtymae Oyj Menetelmä septisen sokin hoitamiseksi
FI20002526A (fi) * 2000-11-17 2002-05-18 Orion Yhtymae Oyj Pyridatsinonijohdannaisten uusi käyttö
FI20002525A (fi) * 2000-11-17 2002-05-18 Orion Yhtymae Oyj Tulehduksenvastaisia aineita
FI20002755A0 (fi) * 2000-12-15 2000-12-15 Orion Yhtymae Oyj Menetelmä erektiilin dysfunktion hoitamiseen
FI20010233A0 (fi) 2001-02-08 2001-02-08 Orion Corp Menetelmä sydämen vajaatoiminnan hoitoon
FI20011464A0 (fi) 2001-07-04 2001-07-04 Orion Corp Yhdistelmäterapia sydämen vajaatoiminnan hoitoon
FI20030015A0 (fi) * 2003-01-03 2003-01-03 Orion Corp Menetelmä munuaisten vajaatoiminnan hoitamiseksi
EP1612204A4 (en) * 2003-03-31 2007-04-11 Daiichi Seiyaku Co HYDRAZONE DERIVATIVE
DE102004011512B4 (de) * 2004-03-08 2022-01-13 Boehringer Ingelheim Vetmedica Gmbh Pharmazeutische Zubereitung enthaltend Pimobendan
US8980894B2 (en) 2004-03-25 2015-03-17 Boehringer Ingelheim Vetmedica Gmbh Use of PDE III inhibitors for the treatment of asymptomatic (occult) heart failure
EP1579862A1 (en) * 2004-03-25 2005-09-28 Boehringer Ingelheim Vetmedica Gmbh Use of PDE III inhibitors for the reduction of heart size in mammals suffering from heart failure
FI20040674A0 (fi) 2004-05-12 2004-05-12 Orion Corp Menetelmä tromboembolisten sairauksien estoon
FI20040675A0 (fi) * 2004-05-12 2004-05-12 Orion Corp Menetelmä sydämen hypertrofian hoitoon ja estoon
MXPA06013825A (es) * 2004-05-28 2007-03-01 Abbott Lab Metodos para tratar a un mamifero antes, durante y despues de un paro cardiaco.
CA2599575A1 (en) 2005-03-14 2006-09-21 Orion Corporation A combination treatment for enhancing diuresis
EP1951227B1 (en) 2005-11-14 2017-04-12 Boehringer Ingelheim Vetmedica GmbH Use of pimobendan for the treatment of asymptomatic (occult) heart failure
EP1920785A1 (en) 2006-11-07 2008-05-14 Boehringer Ingelheim Vetmedica Gmbh Liquid preparation comprising a complex of pimobendan and cyclodextrin
BRPI0806588A2 (pt) * 2007-01-17 2014-05-06 Orion Corp Uso levosimendano para o tratamento da doença valvular crônica.
BRPI0921868A2 (pt) 2008-11-25 2015-12-29 Boehringer Ingelheim Vetmed inibidores de fosfodiesterase tipo iii (pde iii) ou agentes de sensibilizacao de ca2+ para o tratamento de cardiomiopatia hipertrofica
JP5747030B2 (ja) 2009-07-14 2015-07-08 シプラ・リミテッド レボシメンダンの製造方法及びその方法で用いる中間体
WO2013135852A1 (en) 2012-03-15 2013-09-19 Boehringer Ingelheim Vetmedica Gmbh Pharmaceutical tablet formulation for the veterinary medical sector, method of production and use thereof
EP2970145B1 (en) * 2013-03-11 2020-05-06 The Broad Institute, Inc. Compounds and compositions for the treatment of cancer
CN105377235A (zh) 2013-07-19 2016-03-02 勃林格殷格翰动物保健有限公司 含有防腐的醚化的环糊精衍生物的液体水性药物组合物
CN104418810A (zh) * 2013-09-04 2015-03-18 北京博时安泰科技发展有限公司 一种左西孟旦的合成新路线
CN103554033A (zh) * 2013-11-12 2014-02-05 江苏正大清江制药有限公司 一种消旋体(±)- 6-(4-氨基苯基)-4,5-二氢-5-甲基-3(2h)-哒嗪酮的拆分方法
CN103554032A (zh) * 2013-11-12 2014-02-05 江苏正大清江制药有限公司 高光学纯度(-)-6-(4-氨基苯基)-4,5-二氢-5-甲基-3(2h)-哒嗪酮的制备方法
BR122019024673B1 (pt) 2013-12-04 2023-04-11 Boehringer Ingelheim Vetmedica Gmbh Composições farmacêuticas aprimoradas de pimobendan
EP3334404A4 (en) 2015-08-13 2019-02-13 The Broad Institute, Inc. COMPOSITIONS AND METHODS FOR DETECTION OF CANCER CELLS EXPRESSING PDE3A OR SLFN12
CN105784895B (zh) * 2015-10-30 2018-05-22 成都欣捷高新技术开发有限公司 一种用高效液相色谱仪检测左西孟旦中杂质的方法
US10537570B2 (en) 2016-04-06 2020-01-21 Boehringer Ingelheim Vetmedica Gmbh Use of pimobendan for the reduction of heart size and/or the delay of onset of clinical symptoms in patients with asymptomatic heart failure due to mitral valve disease
EP3424908A1 (en) 2017-07-07 2019-01-09 Melody Healthcare Pvt. Ltd. Process for preparation of levosimendan
US9962384B1 (en) * 2017-09-07 2018-05-08 Korea Institute Of Science And Technology Levosimendan compound for preventing or treating tau-related diseases
CN111548310B (zh) * 2020-05-12 2021-07-02 成都欣捷高新技术开发股份有限公司 一种左西孟旦钠晶型及其制备方法
CN111718299B (zh) * 2020-07-23 2023-03-10 成都欣捷高新技术开发股份有限公司 一种左西孟旦钠晶型b及其制备方法
US11760730B2 (en) 2021-01-11 2023-09-19 Navinta, Llc Process for the preparation of high purity Levosimendan

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB228004A (en) * 1924-01-24 1925-01-29 Daimler Co Ltd Improvements in locking devices for sliding windows
JPS58113180A (ja) * 1981-12-28 1983-07-05 Mitsui Toatsu Chem Inc ピリダジノン誘導体
JPS6193169A (ja) * 1984-10-12 1986-05-12 Sankyo Co Ltd ピリダジノン誘導体及びその製法
AU581324B2 (en) * 1985-07-05 1989-02-16 Smith Kline & French Laboratories Limited Substituted 6-phenyl-4,5-dihydro pyradazin-3-ones
JPH0629254B2 (ja) * 1986-09-08 1994-04-20 帝国臓器製薬株式会社 ピリダジノン誘導体
GB8824458D0 (en) * 1988-10-19 1988-11-23 Orion Yhtymae Oy Substituted pyridazinones
GB8903130D0 (en) * 1989-02-11 1989-03-30 Orion Yhtymae Oy Substituted pyridazinones
GB2251615B (en) * 1991-01-03 1995-02-08 Orion Yhtymae Oy (-)-[[4-(1,4,5,6-tetrahydro-4-methyl-6-oxo-3-pyridazinyl)phenyl]hydrazono]pro panedinitrile

Also Published As

Publication number Publication date
NO932367L (no) 1993-06-28
JP2635445B2 (ja) 1997-07-30
CY1878A (en) 1996-04-05
GB9127145D0 (en) 1992-02-19
US5424428A (en) 1995-06-13
DE69201640T2 (de) 1995-08-10
FI105183B (fi) 2000-06-30
IL114028A (en) 1996-09-12
DK0565546T3 (da) 1995-05-22
DE69201640D1 (de) 1995-04-13
PL169435B1 (pl) 1996-07-31
GB2251615A (en) 1992-07-15
SI9112003A (sl) 1998-10-31
GEP19991868B (en) 1999-12-06
FI932618A (fi) 1993-06-09
JPH09183767A (ja) 1997-07-15
IL100553A0 (en) 1992-09-06
NO300682B1 (no) 1997-07-07
RO111847B1 (ro) 1997-02-28
HRP921251B1 (en) 2000-06-30
AU1153592A (en) 1992-08-17
HUT64754A (en) 1994-02-28
NO932367D0 (no) 1993-06-28
LV11174B (en) 1996-12-20
YU48767B (sh) 1999-12-27
AU645399B2 (en) 1994-01-13
RU2118317C1 (ru) 1998-08-27
PL169415B1 (pl) 1996-07-31
BR1100737A (pt) 2000-03-21
ES2070627T3 (es) 1995-06-01
GB2251615B (en) 1995-02-08
IL114028A0 (en) 1995-10-31
HRP921251A2 (en) 1995-08-31
LU90920I2 (en) 2002-07-17
HU218659B (hu) 2000-10-28
BG97915A (bg) 1994-04-29
IL100553A (en) 1995-12-31
EE02946B1 (et) 1996-12-16
EP0565546B1 (en) 1995-03-08
ATE119525T1 (de) 1995-03-15
EP0565546A1 (en) 1993-10-20
JP3015748B2 (ja) 2000-03-06
KR100207145B1 (ko) 1999-07-15
YU200391A (sh) 1994-05-10
KR930703266A (ko) 1993-11-29
US5569657A (en) 1996-10-29
BG62002B1 (bg) 1998-12-30
CA2314115A1 (en) 1992-07-04
WO1992012135A1 (en) 1992-07-23
NO2001021I1 (no) 2001-12-03
IE920002A1 (en) 1992-07-15
CA2099262A1 (en) 1992-07-04
CA2314115C (en) 2004-03-30
NZ241194A (en) 1993-06-25
IE72101B1 (en) 1997-03-12
FI932618A0 (fi) 1993-06-09
LV11174A (lv) 1996-04-20
US5512571A (en) 1996-04-30
CA2099262C (en) 2002-03-12
JPH06504275A (ja) 1994-05-19
HU9301911D0 (en) 1993-09-28

Similar Documents

Publication Publication Date Title
GB2251615B (en) (-)-[[4-(1,4,5,6-tetrahydro-4-methyl-6-oxo-3-pyridazinyl)phenyl]hydrazono]pro panedinitrile
RU93052411A (ru) (-)-энантиомер-{([4-(1,4,5,6-тетрагидро-4-метил-6-оксо-3-пиридазинил)фенил])-гидразоно} пропандинитрил
DE69329381D1 (de) Anti-ischaemisches arzneimittel
ES2108595A1 (es) Derivados de la 3(2h)-piridacinona y procedimiento para su preparacion.
AU3476595A (en) Use of 2,4-diamino pyrimidine 3-oxide or a salt thereof for treating collagen maturation and structuring disorders
PL311296A1 (en) Derivatives of benzo [f] quinoxalinodione, method of obtaining them and their application in therapeutic agents

Legal Events

Date Code Title Description
PF Patent in force
PE Patent expired

Effective date: 20120102